Evidence-based articles on medication tapering, clinical protocols, and the science of safe deprescribing.
Reinstatement — reintroducing the discontinued drug, or a portion of it, to suppress emergent withdrawal — is the most reliable intervention when a taper has destabilized a patient. The clinical problem is rarely whether to reinstate but how much, how fast, and at what point rein
Read more →Serotonin-norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs) share a serotonergic mechanism, but their discontinuation syndromes are not interchangeable. SNRIs, by virtue of their dual reuptake action and the unusually short half-lives
Read more →Pregnancy forces a binary that rarely has a clean answer: continue a psychotropic with known or uncertain fetal exposure, or taper it and accept the risk of maternal relapse. The reflexive instinct to discontinue "to be safe" is frequently the higher-risk decision, because untrea
Read more →Stopping an antidepressant in an adolescent is not a scaled-down version of the adult task. Developmental pharmacokinetics, a steep relapse curve, the FDA boxed warning for suicidality in patients under 25, and the involvement of caregivers and schools all change the calculus at
Read more →The Maudsley Deprescribing Guidelines (Horowitz & Taylor, 2024) are the first formulary-grade manual dedicated to stopping psychotropic medication rather than starting it. They translate the pharmacology of receptor occupancy into concrete tapering schedules for antidepressants,
Read more →The non-benzodiazepine hypnotics — zolpidem, eszopiclone, and zaleplon, collectively the "Z-drugs" — are frequently prescribed for short-term insomnia but are commonly continued for months to years against labeling. Despite marketing that positioned them as safer than benzodiazep
Read more →Trazodone is one of the most widely prescribed off-label hypnotics in primary care and psychiatry, typically at 25–100 mg nightly, despite an FDA indication only for major depressive disorder at 150–600 mg/day. Discontinuation in long-term low-dose users is dominated by rebound i
Read more →A failed taper is a clinical event with downstream consequences: reinstatement decisions, future deprescribing attempts, disability determinations, and — increasingly — litigation involving prescribers who either tapered too aggressively or refused to taper at all. The medical re
Read more →Buspirone (BuSpar) is a non-benzodiazepine anxiolytic with a distinctive pharmacologic profile: a 5-HT1A partial agonist with weak D2 antagonism, no GABAergic activity, and — by FDA labeling and most regulatory guidance — no documented physiological dependence syndrome. Despite t
Read more →Recovery from antidepressant, benzodiazepine, and antipsychotic withdrawal is rarely linear. Patients commonly cycle between symptom-free intervals ("windows") and abrupt symptom returns ("waves"), often without an identifiable trigger. Failing to prepare a patient for this patte
Read more →Lamotrigine occupies an unusual position among CNS-active drugs that prescribers deprescribe: it produces no recognized somatic discontinuation syndrome of the kind seen with SSRIs, SNRIs, or benzodiazepines, yet abrupt cessation carries two distinct and serious risks — rebound s
Read more →SSRI discontinuation syndrome has been characterized in product labeling and older review articles as a self-limited cluster of symptoms resolving within 1–2 weeks. The contemporary evidence base — including the Davies & Read 2019 systematic review in *Addictive Behaviors*, the H
Read more →Low-dose quetiapine (12.5–100 mg nightly) is among the most frequently prescribed off-label hypnotics in primary care and psychiatry, despite no FDA approval for insomnia and limited efficacy data beyond short-term trials. Discontinuation is complicated by histaminergic rebound,
Read more →Monitoring cadence during active deprescribing is one of the most under-specified elements of every major tapering guideline. The Maudsley Deprescribing Guidelines (Horowitz & Taylor, 2024) and NICE NG215 (2022) both endorse hyperbolic dose reductions and patient-paced taper spee
Read more →Supersensitivity psychosis describes a clinically distinct phenomenon in which psychotic symptoms emerge, worsen, or rebound following antipsychotic dose reduction, discontinuation, or even during steady-state treatment with long-term D2 antagonism. First characterized by Chouina
Read more →Escitalopram is one of the most frequently prescribed SSRIs in primary care and psychiatric practice, and its discontinuation profile is increasingly recognised as more problematic than its initial reputation suggested. The combination of a moderately long parent half-life, near-
Read more →Polypharmacy in older adults is one of the most common — and most under-managed — clinical scenarios in primary care and geriatric psychiatry. A patient in their seventies presenting with five or more concurrent CNS-active medications (an antidepressant, a benzodiazepine, a Z-dru
Read more →Mirtazapine occupies an unusual pharmacological niche, and its discontinuation syndrome looks unlike that of SSRIs or SNRIs. The prescriber who treats mirtazapine taper as a clone of sertraline or venlafaxine deprescribing will under-anticipate the histaminergic rebound that driv
Read more →Akathisia emerging during or after psychotropic taper is one of the most clinically dangerous withdrawal phenomena because it is frequently misread as anxiety, agitated relapse, or worsening depression and treated by reinstating or escalating the offending agent. The neurobiologi
Read more →Gabapentin and pregabalin are prescribed across a far wider range of indications than their narrow FDA-approved labels (postherpetic neuralgia, partial seizures, fibromyalgia, diabetic peripheral neuropathy, generalized anxiety disorder in the EU for pregabalin). The off-label vo
Read more →The pre-taper visit is the single highest-leverage clinical encounter in a deprescribing trajectory. Misaligned expectations at this stage account for a disproportionate share of taper failures, premature reinstatement, and patient-prescriber rupture. A structured counseling prot
Read more →The fluoxetine bridge is a cross-taper strategy in which a patient on a short half-life SSRI or SNRI is switched to fluoxetine, then tapered off fluoxetine, exploiting its long elimination half-life to produce a smoother pharmacokinetic offset. It is most often considered for pat
Read more →Tapering strips are pre-packaged daily dose units, compounded by specialty pharmacies, that step a patient down through arithmetic or hyperbolic dose reductions far smaller than commercially available tablet strengths permit. They originated in the Netherlands in 2013 through the
Read more →Clonazepam is among the longer-acting benzodiazepines in routine prescribing, but its long half-life does not, on its own, make discontinuation easy. The pharmacokinetic and pharmacodynamic features that make clonazepam useful for panic disorder, seizure prophylaxis, and certain
Read more →When a patient deteriorates during or shortly after an antidepressant taper, the prescriber faces a high-stakes diagnostic question: is the original disorder returning, or is the patient experiencing pharmacological withdrawal? The answer determines whether to reinstate, slow the
Read more →The relationship between SSRI dose and serotonin transporter (SERT) occupancy is hyperbolic, not linear. This single pharmacological fact reframes nearly every conventional taper plan written on a prescription pad — particularly the closing weeks, where most withdrawal complicati
Read more →Olanzapine produces among the highest sustained D2 receptor occupancy of the second-generation antipsychotics, and abrupt or rapid discontinuation is associated with rebound psychosis, cholinergic withdrawal, and severe insomnia. The pharmacology that makes the drug effective — b
Read more →The "10% rule" — reducing a psychotropic dose by approximately 10% of the *current* dose at each step rather than by a fixed milligram amount — has migrated from harm-reduction guides into peer-reviewed deprescribing literature over the past decade. For prescribers managing antid
Read more →Shared decision-making (SDM) in psychotropic deprescribing is no longer optional. The Maudsley Deprescribing Guidelines (Horowitz & Taylor, 2024), NICE NG215 (2022) on safe medicine withdrawal, and the Royal College of Psychiatrists' 2020 position statement all converge on the sa
Read more →Duloxetine is among the most discontinuation-prone agents in routine psychiatric and pain practice, and its delayed-release enteric-coated bead formulation is poorly suited to gradual dose reduction. The absence of a low-dose oral solution in most markets, combined with a short e
Read more →Post-acute withdrawal syndrome (PAWS) describes a constellation of neuropsychiatric, somatic, and autonomic symptoms that persist or emerge weeks to months after acute discontinuation of a CNS-active drug has resolved. Despite being absent from DSM-5-TR and ICD-11 as a discrete e
Read more →Sertraline is among the most widely prescribed SSRIs in primary care and psychiatry, and discontinuation symptoms are common when reductions are linear with respect to milligram dose rather than to receptor occupancy. The practical problem at the prescriber's desk is that the rel
Read more →Long-term benzodiazepine prescribing remains widespread despite three decades of guidance against it, and abrupt discontinuation in physically dependent patients carries seizure, autonomic instability, and protracted withdrawal risk. Professor C. Heather Ashton's *Benzodiazepines
Read more →Informed consent for stopping a medication receives less attention than consent for starting one, yet the medico-legal and clinical stakes are comparable. Withdrawal phenomena, relapse risk, and the possibility of protracted symptoms after discontinuation of antidepressants, benz
Read more →Benzodiazepine equivalency tables are routine reference tools when transitioning a patient from a short-acting agent to a long-acting one for the purpose of deprescribing. They are also among the most misapplied resources in psychopharmacology, because the published equivalencies
Read more →Hyperbolic tapering of antidepressants requires dose decrements far smaller than the lowest commercially available tablet or capsule strength. For many SSRIs and SNRIs, the final months of a taper involve doses that simply cannot be achieved by splitting tablets or counting beads
Read more →Paroxetine produces discontinuation syndrome at a rate and severity unmatched by any other SSRI, attributable to a combination of potent anticholinergic activity, nonlinear pharmacokinetics, and the absence of active metabolites. For the prescriber managing a patient who has been
Read more →Clinicians managing psychotropic tapers face a consistent practical challenge: how do you reliably track whether a patient is tolerating a dose reduction, getting worse, or recovering? Verbal reports vary; patients often underreport symptoms to avoid disappointing their prescribe
Read more →[venlafaxine (Effexor)](/resources/medications/effexor) holds an unfortunate distinction among antidepressants: it reliably produces some of the most intense and prolonged discontinuation syndromes of any psychiatric medication in common use. Prescribers who follow standard indus
Read more →Antidepressant discontinuation syndrome affects an estimated 56% of patients who attempt to stop treatment, with severity correlating poorly with the absolute dose being reduced and strongly with the proportional change in serotonin transporter (SERT) occupancy. Hyperbolic taperi
Read more →The February 2026 JAMA/ASCP consensus statement formally recognizes structured psychotropic deprescribing as standard of care. Here's what it means for your practice.
Read more →SSRI discontinuation syndrome affects up to 56% of patients who stop abruptly. Learn the evidence-based approach to safe SSRI tapering using hyperbolic dose reductions.
Read more →The Maudsley Guidelines represent a paradigm shift in how we approach medication withdrawal. Here's what matters most for your practice.
Read more →Most taper protocols use linear reductions, but receptor occupancy follows a hyperbolic curve. Understanding this distinction changes how you deprescribe.
Read more →